They found that GLP-1 users had a 37% higher risk of alopecia than those taking SGLT-2 inhibitors, and a 68% higher risk compared with those using DPP-4 inhibitors
Oral precursors and IV delivery are not interchangeable for patients with significant NAD deficiency
For states like Mississippi, West Virginia, and Arkansas, annual GLP-1 costs at commonly prescribed injectable prices can still represent more than 12% of median per capita income, roughly double the national average
Electrolyte Replenishment : When you consume alcohol, your body loses vital electrolytes, which can lead to muscle weakness, dizziness, and nausea
Ipamorelin vs GHRP-2 and GHRP-6 GHRP Family Side-by-Side Feature Receptor Ipamorelin GHS-R1a GHRP-2 GHS-R1a GHRP-6 GHS-R1a Feature Half-life Ipamorelin ~2 hours GHRP-2 ~25-30 minutes GHRP-6 ~20-30 minutes Feature Dosing Ipamorelin 1-3x daily (SubQ) GHRP-2 2-3x daily (SubQ) GHRP-6 2-3x daily (SubQ) Feature Standard dose Ipamorelin 100-300 mcg GHRP-2 100-300 mcg GHRP-6 100-300 mcg Feature Cortisol effect Ipamorelin None at standard doses GHRP-2 Yes GHRP-6 Yes Feature Prolactin effect Ipamorelin None GHRP-2 Moderate GHRP-6 Minimal Feature Appetite effect Ipamorelin Mild GHRP-2 Moderate GHRP-6 Strong Feature FDA status Ipamorelin Not approved GHRP-2 Not approved GHRP-6 Not approved All three target the same receptor
